Gene polymorphisms and pharmacogenetics in rheumatoid arthritis

被引：5
作者：
Rego-Perez, Ignacio [1 ]
Fernandez-Moreno, Mercedes [1 ]
Carreira-Garcia, Vanessa [1 ]
Blanco, Francisco J. [1 ]
机构：
[1] INIBIC, Lab Invest, Div Reumatol, Unidad Invest Envejecimiento Osteoarticular, La Coruna, Spain
来源：
REUMATOLOGIA CLINICA | 2009年 / 5卷 / 06期
关键词：
Pharmacogenetics; Pharmacogenomics; Rheumatoid arthritis; Tumor necrosis factor; Interleukin-1; Cytokines; Gene polymorphisms;
D O I：
10.1016/j.reuma.2008.12.001
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Rheumatoid arthritis (RA) is a systemic, chronic, and inflammatory disease of unknown aetiology with a genetic predisposition. The advent of new biological agents, as well as the more traditional disease-modifying anti rheumatic drugs, has resulted in highly efficient therapies for reducing the symptoms and signs of RA; however, not all patients show the same level of response regarding disease progression to these therapies. These variations suggest that RA patients may have different genetic regulatory mechanisms. The extensive polymorphisms revealed in non-coding gene-regulatory regions in the immune system, as well as genetic variations in drug-metabolizing enzymes, suggest that this type of variation is of functional and evolutionary importance and may provide clues for developing new therapeutic strategies. Pharmacogenetics is a rapidly advancing area of research that holds the promise that therapies will soon be tailored to an individual patient's genetic profile.. Chronic and severe forms of gout are frequently wrongly evaluated from the clinical standpoint. (C) 2008 Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码：268 / 279
页数：12
相关论文
共 113 条
[41]  
Ferraccioli G, 2003, J RHEUMATOL, V30, P2517
[42]   The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis [J].
Fishman, D ;
Faulds, G ;
Jeffery, R ;
Mohamed-Ali, V ;
Yudkin, JS ;
Humphries, S ;
Woo, P .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (07) :1369-1376
[43]   Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis - A large, international, multicenter, placebo-controlled trial [J].
Fleischmann, RM ;
Schechtman, J ;
Bennett, R ;
Handel, ML ;
Burmester, GR ;
Tesser, J ;
Modafferi, D ;
Poulakos, J ;
Sun, G .
ARTHRITIS AND RHEUMATISM, 2003, 48 (04) :927-934
[44]   Polymorphism at position-308 of the tumour necrosis factor α gene and rheumatoid arthritis pharmacogenetics [J].
Fonseca, JE ;
Carvalho, T ;
Cruz, M ;
Nero, P ;
Sobral, M ;
Mourao, AF ;
Cavaleiro, J ;
Ligeiro, D ;
Abreu, I ;
Carmo-Fonseca, M ;
Branco, JC .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (05) :793-794
[45]   Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes [J].
Genovese, MC ;
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Cannon, GW ;
Spencer-Green, G ;
Finck, BK .
ARTHRITIS AND RHEUMATISM, 2002, 46 (06) :1443-1450
[46]  
Greenberg JD, 2007, BULL HOSP JT DIS, V65, P139
[47]   THE SHARED EPITOPE HYPOTHESIS - AN APPROACH TO UNDERSTANDING THE MOLECULAR-GENETICS OF SUSCEPTIBILITY TO RHEUMATOID-ARTHRITIS [J].
GREGERSEN, PK ;
SILVER, J ;
WINCHESTER, RJ .
ARTHRITIS AND RHEUMATISM, 1987, 30 (11) :1205-1213
[48]   Regulatory functions of 3′UTRs [J].
Grzybowska, EA ;
Wilczynska, A ;
Siedlecki, JA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 288 (02) :291-295
[49]  
Guignard S, 2007, CLIN EXP RHEUMATOL, V25, P758
[50]   Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis [J].
Haagsma, CJ ;
Blom, HJ ;
van Riel, PLCM ;
van't Hof, MA ;
Giesendorf, BAJ ;
van Oppenraaij-Emmerzaal, D ;
van de Putte, LBA .
ANNALS OF THE RHEUMATIC DISEASES, 1999, 58 (02) :79-84
12345678910